<DOC>
	<DOCNO>NCT00003755</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness Ro 31-7453 treating patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Ro 31-7453 Treating Patients With Locally Advanced Metastatic Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose Ro 31-7453 patient solid tumor . II . Determine toxicity Ro 31-7453 patient population . III . Evaluate pharmacokinetics major metabolite Ro 31-7453 patient . IV . Assess antitumor activity Ro 31-7453 patient . OUTLINE : This dose escalation study . Patients treat one two treatment arm . In first stage , cohorts 1 patient arm I receive oral Ro 31-7453 twice daily day 1-4 , cohorts 1 patient arm II receive oral Ro 31-7453 daily day 1-4 two dose level higher arm I . Dose escalation cease arm first instance dose limit toxicity ( DLT ) . Two additional patient enter stop dose arm . If DLT occur , study proceeds second stage . In second stage , dose escalation continue increment one dose level dose schedule ( arm I II ) . Cohorts 3-6 patient receive escalate dos Ro 31-7453 absence DLT . If 2 6 patient experience DLT dose level , escalation cease maximum tolerate dose define previous dose level . Treatment continue every 3 week 8 course absence disease progression unacceptable toxicity . After completion 8 course , patient may continue treatment disease progression discretion investigator study sponsor . Patients follow 4 week . PROJECTED ACCRUAL : A maximum 40 patient accrue study 18 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced and/or metastatic solid tumor standard therapy available No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 9 g/dL WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT and/or AST great 2.5 time ULN ( great 4.0 time ULN liver bone metastasis present ) Alkaline phosphatase great 2.5 time ULN ( great 4.0 time ULN liver bone metastasis present ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No history serious medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since mitomycin nitrosoureas ) Endocrine therapy : At least 4 week since prior hormonal therapy Concurrent antiandrogen therapy allow Radiotherapy : At least 4 week since prior extend field radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>